OpGen, Inc. (OPGN)
USD 1.07
(-3.6%)
USD 1.07
(-3.6%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -32.66 Million USD | 11.09% |
| 2022 | -36.74 Million USD | -5.56% |
| 2021 | -34.8 Million USD | -32.79% |
| 2020 | -26.21 Million USD | -123.78% |
| 2019 | -11.71 Million USD | 7.33% |
| 2018 | -12.63 Million USD | 17.89% |
| 2017 | -15.39 Million USD | 19.69% |
| 2016 | -19.16 Million USD | -10.46% |
| 2015 | -17.35 Million USD | -205.95% |
| 2014 | -5.67 Million USD | 44.04% |
| 2013 | -10.13 Million USD | 28.67% |
| 2012 | -14.2 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 386.03 Thousand USD | 102.27% |
| 2024 Q2 | -1.57 Million USD | -508.35% |
| 2023 FY | -32.66 Million USD | 11.09% |
| 2023 Q4 | -17.04 Million USD | -319.44% |
| 2023 Q1 | -7.02 Million USD | 29.61% |
| 2023 Q2 | -5.82 Million USD | 16.99% |
| 2023 Q3 | -4.06 Million USD | 30.28% |
| 2022 Q1 | -7.76 Million USD | -12.39% |
| 2022 Q4 | -9.97 Million USD | 32.13% |
| 2022 FY | -36.74 Million USD | -5.56% |
| 2022 Q3 | -14.69 Million USD | -129.3% |
| 2022 Q2 | -6.4 Million USD | 17.43% |
| 2021 Q4 | -6.9 Million USD | -14.02% |
| 2021 Q1 | -14.85 Million USD | -108.86% |
| 2021 FY | -34.8 Million USD | -32.79% |
| 2021 Q2 | -7.08 Million USD | 52.28% |
| 2021 Q3 | -6.05 Million USD | 14.53% |
| 2020 FY | -26.21 Million USD | -123.78% |
| 2020 Q4 | -7.11 Million USD | 7.36% |
| 2020 Q2 | -7.47 Million USD | -89.29% |
| 2020 Q3 | -7.67 Million USD | -2.67% |
| 2020 Q1 | -3.94 Million USD | -56.85% |
| 2019 FY | -11.71 Million USD | 7.33% |
| 2019 Q1 | -3.85 Million USD | -3.23% |
| 2019 Q4 | -2.51 Million USD | 27.7% |
| 2019 Q3 | -3.48 Million USD | -34.3% |
| 2019 Q2 | -2.59 Million USD | 32.7% |
| 2018 Q4 | -3.73 Million USD | -14.65% |
| 2018 Q3 | -3.25 Million USD | 2.3% |
| 2018 Q1 | -3.04 Million USD | -3.74% |
| 2018 FY | -12.63 Million USD | 17.89% |
| 2018 Q2 | -3.33 Million USD | -9.32% |
| 2017 FY | -15.39 Million USD | 19.69% |
| 2017 Q4 | -2.93 Million USD | 10.11% |
| 2017 Q3 | -3.26 Million USD | 22.32% |
| 2017 Q2 | -4.2 Million USD | 15.47% |
| 2017 Q1 | -4.97 Million USD | -4.58% |
| 2016 Q1 | -4.5 Million USD | 4.69% |
| 2016 FY | -19.16 Million USD | -10.46% |
| 2016 Q4 | -4.76 Million USD | 1.81% |
| 2016 Q3 | -4.84 Million USD | 4.06% |
| 2016 Q2 | -5.05 Million USD | -12.13% |
| 2015 Q2 | -5.35 Million USD | -106.48% |
| 2015 Q1 | -2.59 Million USD | -84.63% |
| 2015 Q3 | -4.67 Million USD | 12.84% |
| 2015 Q4 | -4.72 Million USD | -1.22% |
| 2015 FY | -17.35 Million USD | -205.95% |
| 2014 Q1 | -1.2 Million USD | 70.76% |
| 2014 Q4 | -1.4 Million USD | 12.63% |
| 2014 Q3 | -1.6 Million USD | -10.43% |
| 2014 FY | -5.67 Million USD | 44.04% |
| 2014 Q2 | -1.45 Million USD | -21.38% |
| 2013 Q4 | -4.1 Million USD | 0.0% |
| 2013 FY | -10.13 Million USD | 28.67% |
| 2012 FY | -14.2 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bionano Genomics, Inc. | -232.49 Million USD | 85.949% |
| Prenetics Global Limited | -62.72 Million USD | 47.917% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -2010.37% |
| CareDx, Inc | -190.28 Million USD | 82.832% |
| Exact Sciences Corporation | -204.14 Million USD | 83.998% |
| Exagen Inc. | -23.68 Million USD | -37.906% |
| Inotiv, Inc. | -105.14 Million USD | 68.929% |
| Guardant Health, Inc. | -479.44 Million USD | 93.186% |
| Biodesix, Inc. | -52.14 Million USD | 37.352% |
| BioNexus Gene Lab Corp. | -2.62 Million USD | -1142.602% |
| Precipio, Inc. | -5.85 Million USD | -458.15% |
| iSpecimen Inc. | -11.09 Million USD | -194.325% |
| Natera, Inc. | -434.8 Million USD | 92.487% |
| Aspira Women's Health Inc. | -16.69 Million USD | -95.737% |
| Standard BioTools Inc. | -74.65 Million USD | 56.241% |
| 23andMe Holding Co. | -666.7 Million USD | 95.1% |
| Castle Biosciences, Inc. | -57.46 Million USD | 43.152% |
| Personalis, Inc. | -108.29 Million USD | 69.834% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 63.078% |
| Applied DNA Sciences, Inc. | -9.94 Million USD | -228.424% |
| T2 Biosystems, Inc. | -50.07 Million USD | 34.763% |
| Myriad Genetics, Inc. | -112 Million USD | 70.832% |
| ICON Public Limited Company | 612.33 Million USD | 105.335% |
| NeoGenomics, Inc. | -87.96 Million USD | 62.863% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -2010.37% |
| IDEXX Laboratories, Inc. | 845.04 Million USD | 103.866% |
| RadNet, Inc. | 3.04 Million USD | 1173.211% |
| MDxHealth SA | -43.1 Million USD | 24.203% |
| Psychemedics Corporation | -4.15 Million USD | -686.435% |
| Illumina, Inc. | -1.16 Billion USD | 97.186% |
| Check-Cap Ltd. | -17.56 Million USD | -85.955% |
| Twist Bioscience Corporation | -208.72 Million USD | 84.349% |
| DarioHealth Corp. | -59.42 Million USD | 45.027% |
| Fulgent Genetics, Inc. | -167.82 Million USD | 80.534% |
| Sera Prognostics, Inc. | -36.24 Million USD | 9.86% |
| ENDRA Life Sciences Inc. | -10.06 Million USD | -224.729% |
| OPKO Health, Inc. | -188.86 Million USD | 82.703% |
| Medpace Holdings, Inc. | 282.81 Million USD | 111.551% |
| Neogen Corporation | -9.42 Million USD | -246.763% |
| Intelligent Bio Solutions Inc. | -10.15 Million USD | -221.643% |
| Prenetics Global Limited | -62.72 Million USD | 47.917% |
| Mainz Biomed B.V. | -26.29 Million USD | -24.235% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -311.597% |
| Trinity Biotech plc | -24.01 Million USD | -36.017% |
| Neuronetics, Inc. | -30.18 Million USD | -8.213% |
| Sotera Health Company | 51.37 Million USD | 163.587% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -311.597% |